BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY

被引：0
|
作者：
Kolbin, A. [1 ]
Frolov, M. [2 ]
Kurylev, A. [1 ]
Vilum, I [1 ]
Balykina, Y. [3 ]
Proskurin, M. [3 ]
机构：
[1] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia
[2] Volgograd State Med Univ, Volgograd, Russia
[3] St Petersburg State Univ, St Petersburg, Russia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1095
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN79
引用
收藏
页码：A443 / A443
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS FOR NILOTINIB USE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN COLOMBIA
    Romero, M.
    Acero, G.
    Marrugo, R.
    VALUE IN HEALTH, 2014, 17 (03) : A75 - A75
  • [2] BUDGET IMPACT ANALYSIS OR PHARMACOLOGICAL THERAPY OF CHRONIC MYELOID LEUKEMIA (CML) WITH NILOTINIB AS THE SECOND-LINE TREATMENT IN RUSSIAN FEDERATION
    Serpik, V. G.
    Yagudina, R.
    VALUE IN HEALTH, 2015, 18 (07) : A442 - A442
  • [3] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [4] Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
    Breccia, Massimo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 129 - 134
  • [5] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [6] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [7] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
    McFarland, K. Leigh
    Wetzstein, Gene A.
    CANCER CONTROL, 2009, 16 (02) : 132 - 140
  • [8] Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Fogli, Miriam
    Cavo, Michele
    Baccarani, Michele
    Rosti, Gianantonio
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 563 - 574
  • [9] THE BUDGET IMPACT ANALYSIS OF NILOTINIB IN THE SECOND-LINE TREATMENT OF IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA
    Huang, C.
    Shen, L.
    Liu, Y.
    VALUE IN HEALTH, 2018, 21 : S96 - S96
  • [10] Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors
    Ribeiro, Beatriz F.
    Miranda, Eliana C. M.
    Delamain, Marcia T.
    Oliveira, Gislaine Borba
    Almeida, Maria Helena
    Duarte, Vagner O.
    Metze, Irene L.
    De Souza, Carmino A.
    Silveira, Rosana A.
    Pagnano, Katia B.
    BLOOD, 2013, 122 (21)
12345